RSS-Feed abonnieren
DOI: 10.1055/s-2006-956273
© Georg Thieme Verlag KG Stuttgart · New York
Subklinische Albuminurie, Mikroalbuminurie und Proteinurie - akzeptierte kardiovaskuläre Risikomarker?
Low grade albuminuria, microalbuminuria and proteinuria - accepted cardiovascular risk markers?Publikationsverlauf
eingereicht: 23.5.2006
akzeptiert: 26.10.2006
Publikationsdatum:
16. November 2006 (online)

Zusammenfassung
Die Mikroalbuminurie kommt in der Allgemeinbevölkerung häufig vor, insbesondere bei Patienten mit Diabetes mellitus oder arteriellem Bluthochdruck. Sie gilt als Indikator für eine endotheliale Dysfunktion. Bei Vorliegen einer Mikroalbuminurie ist nicht nur das Risiko für die Progression von Nierenerkrankungen erhöht, sondern auch das für kardiovaskuläre Ereignisse und Todesfälle. Aktuelle Studienergebnisse belegen, dass letztere schon bei einer Albuminausscheidung, die deutlich unterhalb der Grenze zur Mikroalbuminurie liegt, gehäuft auftreten. Man findet also eine kontinuierliche Risikoerhöhung bei ansteigenden Albuminwerten. Somit bietet die Bestimmung der Albuminausscheidung im Urin eine einfache, schnelle, und kostengünstige Methode zur Identifizierung von Personen mit einem erhöhten kardiovaskulären Risiko. Aus therapeutischer Sicht geht eine Reduktion der Mikroalbuminurie durch die Hemmung des Renin-Angiotensin-Systems (RAS) durch ACE-Hemmer oder AT1-Blocker mit einer Abnahme des Risikos für kardiovaskuläre Ereignisse einher.
Summary
Microalbuminuria is regarded as a marker of endothelial dysfunction. It is common in the general population, particularly in patients with diabetes mellitus or arterial hypertension. Microalbuminuria not only increases the risk for the progression of chronic nephropathy, but also for cardiovascular complications and death. According to recent study results, a slightly elevated urinary albumin excretion within the normal range is already associated with an increased risk for cardiovascular events. Thus there is a continous rise in risk with rising albumin excretion determination of urinary albumin excretion offers an easy, rapid, and cheap approach to identify subjects with elevated cardiovascular risk. From a therapeutic perspective, reduction of microalbuminuria by inhibition of the renin-angiotensin system (RAS) with ACE inhibitors or AT1 blockers is accompanied by a lower incidence of cardiovascular events.
Schlüsselwörter
Mikroalbuminurie - Albuminurie - Proteinurie - endotheliale Dysfunktion - kardiovaskuläres Risiko - Renin-Angiotensin-System - Albumin-Kreatinin-Quotient - Screening - Prävention
Key words
microalbuminuria - albuminuria - proteinuria - endothelial dysfunction - cardiovascular risk - renin angiotensin system - urinary albumin creatinine ratio - screening - prevention
Literatur
- 1 Plan and operation of the Third National Health and Nutrition Examination Survey,
1988 - 94. Series 1: programs and collection procedures. 1 Vital Health Stat 1994: 1-407
MissingFormLabel
- 2
2003 European Society of Hypertension-European Society of Cardiology guidelines for
the management of arterial hypertension.
J Hypertens.
2003;
21
1011-1053
MissingFormLabel
- 3
American Diabetes Association .
Diabetic Nephropathy.
Diabetes Care.
2002;
25
85-89
MissingFormLabel
- 4
Arnlov J, Evans J C, Meigs J B. et al .
Low-Grade Albuminuria and Incidence of Cardiovascular Disease Events in Nonhypertensive
and Nondiabetic Individuals: The Framingham Heart Study.
Circulation.
2005;
112
969-975
MissingFormLabel
- 5
Asselbergs F W, Diercks G F, Hillege H L. et al .
Effects of fosinopril and pravastatin on cardiovascular events in subjects with microalbuminuria.
Circulation.
2004;
110
2809-2816
MissingFormLabel
- 6
Berton G, Cordiano R, Palmieri R, Cucchini F, De Toni R, Palatini P.
Microalbuminuria during acute myocardial infarction: a strong predictor for 1-year
mortality.
Eur Heart J.
2001;
22
1466-1475
MissingFormLabel
- 7
Borch-Johnsen K, Feldt-Rasmussen B, Strandgaard S, Schroll M, Jensen J S.
Urinary albumin excretion. An independent predictor of ischemic heart disease.
Arterioscler Thromb Vasc Biol.
1999;
19
1992-1997
MissingFormLabel
- 8
Boright A P, Paterson A D, Mirea L. et al .
Genetic variation at the ACE gene is associated with persistent microalbuminuria and
severe nephropathy in type 1 diabetes: the DCCT/EDIC Genetics Study.
Diabetes.
2005;
54
1238-1244
MissingFormLabel
- 9
Bramlage P, Pittrow D, Kirch W.
The effect of irbesartan in reducing cardiovascular risk in hypertensive type 2 diabetic
patients: an observational study in 16,600 patients in primary care.
Curr Med Res Opin.
2004;
20
1625-1631
MissingFormLabel
- 10
Bramlage P, Pittrow D, Lehnert H. et al .
Frequency of albuminuria in primary care: a cross sectional study.
Eur J Cardiovasc Prev Rehabil.
13; 6
(im Druck);
MissingFormLabel
- 11
Brenner B M, Cooper M E, de Zeeuw D. et al .
Effects of Losartan on Renal and Cardiovascular Outcomes in Patients with Type 2 Diabetes
and Nephropathy.
N Engl J Med.
2001;
345
861-869
MissingFormLabel
- 12
Brenner B M, Meyer T W, Hostetter T H.
Dietary protein intake and the progressive nature of kidney disease: the role of hemodynamically
mediated glomerular injury in the pathogenesis of progressive glomerular sclerosis
in aging, renal ablation, and intrinsic renal disease.
N Engl J Med.
1982;
307
652-659
MissingFormLabel
- 13
Casas J P, Chua W, Loukogeorgakis S. et al .
Effect of inhibitors of the renin-angiotensin system and other antihypertensive drugs
on renal outcomes: systematic review and meta-analysis.
Lancet.
2005;
366
2026-2033
MissingFormLabel
- 14
Coresh J, Astor B, Greene T, Eknoyan G, Levey A.
Prevalence of chronic kidney disease and decreased kidney function in the adult US
population: Third National Health and Nutrition Examination Survey.
Am J Kidney Dis.
2003;
41
1-12
MissingFormLabel
- 15
Dahlof B, Devereux R B, Kjeldsen S E. et al .
Cardiovascular morbidity and mortality in the Losartan Intervention For Endpoint reduction
in hypertension study (LIFE): a randomised trial against atenolol.
Lancet.
2002;
359
995-1003
MissingFormLabel
- 16
Damsgaard E M, Froland A, Jorgensen O D, Morgensen C E.
Prognostic value of urinary albumin excretion rate and other risk factors in elderly
diabetic patients and non-diabetic control subjects surviving the first 5 years after
assessment.
Diabetologia.
1993;
36
1030-1036
MissingFormLabel
- 17
de Zeeuw D, Remuzzi G, Parving H H. et al .
Albuminuria, a therapeutic target for cardiovascular protection in type 2 diabetic
patients with nephropathy.
Circulation.
2004;
110
921-927
MissingFormLabel
- 18
de Zeeuw D, Remuzzi G, Parving H H. et al .
Proteinuria, a target for renoprotection in patients with type 2 diabetic nephropathy:
lessons from RENAAL.
Kidney Int.
2004;
65
2309-2320
MissingFormLabel
- 19
Deckert T, Feldt-Rasmussen B, Borch-Johnsen K, Jensen T, Kofoed-Enevoldsen A.
Albuminuria reflects widespread vascular damage. The Steno hypothesis.
Diabetologia.
1989;
32
219-226
MissingFormLabel
- 20
Deckert T, Feldt-Rasmussen B, Djurup R, Deckert M.
Glomerular size and charge selectivity in insulin-dependent diabetes mellitus.
Kidney Int.
1988;
33
100-106
MissingFormLabel
- 21
Deutsche Diabetes Gesellschaft .
Praxis-Leitlinien der Deutschen Diabetes-Gesellschaft (DDG).
Diabetes und Stoffwechsel.
2002;
11
1-39
MissingFormLabel
- 22
Diercks G F, Hillege H L, van Boven A J. et al .
Microalbuminuria modifies the mortality risk associated with electrocardiographic
ST-T segment changes.
J Am Coll Cardiol.
2002;
40
1401-1407
MissingFormLabel
- 23
Diercks G F, van Boven A J, Hillege H L. et al .
Microalbuminuria is independently associated with ischaemic electrocardiographic abnormalities
in a large non-diabetic population. The PREVEND (Prevention of REnal and Vascular
ENdstage Disease) study.
Eur Heart J.
2000;
21
1922-1927
MissingFormLabel
- 24
Dinneen S F, Gerstein H C.
The association of microalbuminuria and mortality in non-insulin-dependent diabetes
mellitus. A systematic overview of the literature.
Arch Intern Med.
1997;
157
1413-1418
MissingFormLabel
- 25
Fernandez F, Paez P, Hermosin B, Vazquez G, Ortiz C, Tarilonte D.
Rapid screening test evaluation for microalbuminuria in diabetes mellitus.
Acta Diabetol.
1998;
35
199-202
MissingFormLabel
- 26
Garg A X, Kiberd B A, Clark W F, Haynes R B, Clase C M.
Albuminuria and renal insufficiency prevalence guides population screening: results
from the NHANES III.
Kidney Int.
2002;
61
2165-2175
MissingFormLabel
- 27
Gerber L, Johnston K, Alderman M.
Assessment of a new dipstick test in screening for microalbuminuria in patients with
hypertension.
Am J Hypertens.
1998;
11
1321-1327
MissingFormLabel
- 28
Gerstein H C, Mann J F, Yi Q. et al .
Albuminuria and risk of cardiovascular events, death, and heart failure in diabetic
and nondiabetic individuals.
Jama.
2001;
286
421-426
MissingFormLabel
- 29
Hillege H L, Fidler V, Diercks G F. et al .
Urinary albumin excretion predicts cardiovascular and noncardiovascular mortality
in general population.
Circulation.
2002;
106
1777-1782
MissingFormLabel
- 30
Hillege H L, Janssen W M, Bak A A. et al .
Microalbuminuria is common, also in a nondiabetic, nonhypertensive population, and
an independent indicator of cardiovascular risk factors and cardiovascular morbidity.
J Intern Med.
2001;
249
519-526
MissingFormLabel
- 31
Hoogeveen E K, Kostense P J, Jager A. et al .
Serum homocysteine level and protein intake are related to risk of microalbuminuria:
the Hoorn Study.
Kidney Int.
1998;
54
203-209
MissingFormLabel
- 32
Ibsen H, Olsen M H, Wachtell K. et al .
Reduction in albuminuria translates to reduction in cardiovascular events in hypertensive
patients: losartan intervention for endpoint reduction in hypertension study.
Hypertension.
2005;
45
198-202
MissingFormLabel
- 33
Jensen J S, Borch-Johnsen K, Jensen G, Feldt-Rasmussen B.
Microalbuminuria reflects a generalized transvascular albumin leakiness in clinically
healthy subjects.
Clin Sci (Lond).
1995;
88
629-633
MissingFormLabel
- 34
Jones C A, Francis M E, Eberhardt M S. et al .
Microalbuminuria in the US population: third National Health and Nutrition Examination
Survey.
Am J Kidney Dis.
2002;
39
445-459
MissingFormLabel
- 35
Kverneland A, Feldt-Rasmussen B, Vidal P. et al .
Evidence of changes in renal charge selectivity in patients with type 1 (insulin-dependent)
diabetes mellitus.
Diabetologia.
1986;
29
634-639
MissingFormLabel
- 36
Lewis E J, Hunsicker L G, Bain R P, Rohde R D.
The effect of angiotensin-converting-enzyme inhibition on diabetic nephropathy. The
Collaborative Study Group.
N Engl J Med.
1993;
329
1456-1462
MissingFormLabel
- 37
Lewis E J, Hunsicker L G, Clarke W R. et al .
Renoprotective effect of the angiotensin-receptor antagonist irbesartan in patients
with nephropathy due to type 2 diabetes.
N Engl J Med.
2001;
345
851-860
MissingFormLabel
- 38
Ljungman S, Wikstrand J, Hartford M, Berglund G.
Urinary albumin excretion - a predictor of risk of cardiovascular disease. A prospective
10-year follow-up of middle-aged nondiabetic normal and hypertensive men.
Am J Hypertens.
1996;
9
770-778
MissingFormLabel
- 39
Lum G.
How effective are screening tests for microalbuminuria in random urine specimens?.
Ann Clin Lab Sci.
2000;
30
406-411
MissingFormLabel
- 40
Mann J F, Gerstein H C, Pogue J, Bosch J, Yusuf S.
Renal insufficiency as a predictor of cardiovascular outcomes and the impact of ramipril:
the HOPE randomized trial.
Ann Intern Med.
2001;
134
629-636
MissingFormLabel
- 41
Marre M, Lievre M, Chatellier G, Mann J F, Passa P, Menard J.
Effects of low dose ramipril on cardiovascular and renal outcomes in patients with
type 2 diabetes and raised excretion of urinary albumin: randomised, double blind,
placebo controlled trial (the DIABHYCAR study).
Bmj.
2004;
328
495-499
MissingFormLabel
- 42
Miettinen H, Haffner S M, Lehto S, Ronnemaa T, Pyorala K, Laakso M.
Proteinuria predicts stroke and other atherosclerotic vascular disease events in nondiabetic
and non-insulin-dependent diabetic subjects.
Stroke.
1996;
27
2033-2039
MissingFormLabel
- 43
Mykkanen L, Haffner S M, Kuusisto J, Pyorala K, Laakso M.
Microalbuminuria precedes the development of NIDDM.
Diabetes.
1994;
43
552-557
MissingFormLabel
- 44
Niskanen L, Turpeinen A, Penttila I, Uusitupa M I.
Hyperglycemia and compositional lipoprotein abnormalities as predictors of cardiovascular
mortality in type 2 diabetes: a 15-year follow-up from the time of diagnosis.
Diabetes Care.
1998;
21
1861-1869
MissingFormLabel
- 45 Ochs L, Benson V. Evaluation of a new Micral microalbuminuria urine test strip. Data on file. Indianapolis, IN 46 250: Boehringer Mannheim Corporation 1995
MissingFormLabel
- 46
Parving H H, Lehnert H, Brochner-Mortensen J, Gomis R, Andersen S, Arner P.
The effect of irbesartan on the development of diabetic nephropathy in patients with
type 2 diabetes.
N Engl J Med.
2001;
345
870-878
MissingFormLabel
- 47
Pickup J C, Mattock M B, Chusney G D, Burt D.
NIDDM as a disease of the innate immune system: association of acute-phase reactants
and interleukin-6 with metabolic syndrome X.
Diabetologia.
1997;
40
1286-1292
MissingFormLabel
- 48
Piehlmeier W, Renner R, Schramm W. et al .
Screening of diabetic patients for microalbuminuria in primary care - The PROSIT-Project.
Proteinuria Screening and Intervention.
Exp Clin Endocrinol Diabetes.
1999;
107
244-251
MissingFormLabel
- 49
Pittrow D, Wittchen H, Bramlage P. et al .
Nephropathie - ein Überblick über die tägliche Praxis.
Fortschr Med.
2003;
121
39-44
MissingFormLabel
- 50
Pourdjabbar A, Lapointe N, Rouleau J L.
Angiotensin receptor blockers: powerful evidence with cardiovascular outcomes?.
Can J Cardiol.
2002;
(Suppl A)
18
7A-14A
MissingFormLabel
- 51
Remuzzi G, Bertani T.
Pathophysiology of progressive nephropathies.
N Engl J Med.
1998;
339
1448-1456
MissingFormLabel
- 52
Romundstad S, Holmen J, Kvenild K, Hallan H, Ellekjaer H.
Microalbuminuria and all-cause mortality in 2,089 apparently healthy individuals:
a 4.4-year follow-up study. The Nord-Trondelag Health Study (HUNT), Norway.
Am J Kidney Dis.
2003;
42
466-473
MissingFormLabel
- 53
Rossing K, Schjoedt K J, Jensen B R, Boomsma F, Parving H H.
Enhanced renoprotective effects of ultrahigh doses of irbesartan in patients with
type 2 diabetes and microalbuminuria.
Kidney Int.
2005;
68
1190-1198
MissingFormLabel
- 54
Sarnak M J, Levey A S, Schoolwerth A C. et al .
Kidney disease as a risk factor for development of cardiovascular disease: a statement
from the American Heart Association Councils on Kidney in Cardiovascular Disease,
High Blood Pressure Research, Clinical Cardiology, and Epidemiology and Prevention.
Circulation.
2003;
108
2154-2169
MissingFormLabel
- 55
Schmieder R E, Klingbeil A U, Fleischmann E H, Veelken R, Delles C.
Additional antiproteinuric effect of ultrahigh dose candesartan: a double-blind, randomized,
prospective study.
J Am Soc Nephrol.
2005;
16
3038-3045
MissingFormLabel
- 56
Schmitz A, Vaeth M.
Microalbuminuria: a major risk factor in non-insulin-dependent diabetes. A 10-year
follow-up study of 503 patients.
Diabet Med.
1988;
5
126-134
MissingFormLabel
- 57
Schrader J, Lüders S, Kulschewski A. et al .
Microalbuminuria and tubular proteinuria as risk predictors of cardiovascular morbidity
in essential hypertension: final results of a long-term prospective study (MARPLE
Study) (im Druck).
J Hypertens.
2006;
24
541-548
MissingFormLabel
- 58
Staessen J A, Wang J G, Ginocchio G. et al .
The deletion/insertion polymorphism of the angiotensin converting enzyme gene and
cardiovascular-renal risk.
J Hypertens.
1997;
15
1579-1592
MissingFormLabel
- 59
Tarnow L, Gluud C, Parving H H.
Diabetic nephropathy and the insertion/deletion polymorphism of the angiotensin-converting
enzyme gene.
Nephrol Dial Transplant.
1998;
13
1125-1130
MissingFormLabel
- 60
Valmadrid C T, Klein R, Moss S E, Klein B E.
The risk of cardiovascular disease mortality associated with microalbuminuria and
gross proteinuria in persons with older-onset diabetes mellitus.
Arch Intern Med.
2000;
160
1093-1100
MissingFormLabel
- 61
Vestbo E, Damsgaard E, Froland A, Mogensen C.
Urinary albumin excretion in a population based cohort.
Diabet Med.
1995;
12
488-493
MissingFormLabel
- 62
Wachtell K, Ibsen H, Olsen M H. et al .
Albuminuria and cardiovascular risk in hypertensive patients with left ventricular
hypertrophy: the LIFE study.
Ann Intern Med.
2003;
139
901-906
MissingFormLabel
- 63
Wang S L, Head J, Stevens L, Fuller J H.
Excess mortality and its relation to hypertension and proteinuria in diabetic patients.
The world health organization multinational study of vascular disease in diabetes.
Diabetes Care.
1996;
19
305-312
MissingFormLabel
- 64
Wang T J, Evans J C, Meigs J B. et al .
Low-grade albuminuria and the risks of hypertension and blood pressure progression.
Circulation.
2005;
111
1370-1376
MissingFormLabel
- 65
Yamaji T, Fukuhara T, Kinoshita M.
Increased capillary permeability to albumin in diabetic rat myocardium.
Circ Res.
1993;
72
947-957
MissingFormLabel
- 66
Yusuf S, Sleight P, Pogue J, Bosch J, Davies R, Dagenais G.
Effects of an angiotensin-converting-enzyme inhibitor, ramipril, on cardiovascular
events in high-risk patients. The Heart Outcomes Prevention Evaluation Study Investigators.
N Engl J Med.
2000;
342
145-153
MissingFormLabel
- 67
Yuyun M F, Khaw K T, Luben R. et al .
A prospective study of microalbuminuria and incident coronary heart disease and its
prognostic significance in a British population: the EPIC-Norfolk study.
Am J Epidemiol.
2004;
159
284-293
MissingFormLabel
- 68
Zelmanovitz T, Gross J, Oliveira J, Paggi A, Tatsch M, Azevedo M.
The receiver operating characteristics curve in the evaluation of a random urine specimen
as a screening test for diabetic nephropathy.
Diabetes Care.
1997;
20
516-519
MissingFormLabel
Prof. Dr. Roland E. Schmieder
Medizinische Klinik 4 der Universität Erlangen-Nürnberg, Schwerpunkt Nieren- und Hochdruckkrankheiten
Krankenhausstraße 12
91054 Erlangen
Telefon: 09131/8536245
Fax: 09131/8539209
eMail: roland.schmieder@rzmail.uni-erlangen.de